Comment on “Market Exclusivity for Drugs with Multiple Orphan Approvals (1983–2017) and Associated Budget Impact in the US”

被引：0
|
作者：
Richard Manning
机构：
[1] Bates White,
[2] LLC,undefined
来源：
PharmacoEconomics | 2020年 / 38卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1373 / 1374
页数：1
相关论文
共 9 条
  • [1] Comment on "Market Exclusivity for Drugs with Multiple Orphan Approvals (1983-2017) and Associated Budget Impact in the US"
    Manning, Richard
    PHARMACOECONOMICS, 2020, 38 (12) : 1373 - 1374
  • [2] Reply to Comment on “Market Exclusivity for Drugs with Multiple Orphan Approvals (1983–2017) and Associated Budget Impact in the US”
    William V. Padula
    Sonal Parasrampuria
    Mariana P. Socal
    Rena M. Conti
    Gerard F. Anderson
    PharmacoEconomics, 2020, 38 : 1375 - 1376
  • [3] Market Exclusivity for Drugs with Multiple Orphan Approvals (1983–2017) and Associated Budget Impact in the US
    William V. Padula
    Sonal Parasrampuria
    Mariana P. Socal
    Rena M. Conti
    Gerard F. Anderson
    PharmacoEconomics, 2020, 38 : 1115 - 1121
  • [4] Reply to Comment on "Market Exclusivity for Drugs with Multiple Orphan Approvals (1983-2017) and Associated Budget Impact in the US"
    Padula, William V.
    Parasrampuria, Sonal
    Socal, Mariana P.
    Conti, Rena M.
    Anderson, Gerard F.
    PHARMACOECONOMICS, 2020, 38 (12) : 1375 - 1376
  • [5] Market Exclusivity for Drugs with Multiple Orphan Approvals (1983-2017) and Associated Budget Impact in the US
    Padula, William V.
    Parasrampuria, Sonal
    Socal, Mariana P.
    Conti, Rena M.
    Anderson, Gerard F.
    PHARMACOECONOMICS, 2020, 38 (10) : 1115 - 1121
  • [6] ECONOMIC IMPACT OF THE END OF THE MARKET EXCLUSIVITY FOR ORPHAN DRUGS
    Kandel, M.
    Degrassat-Theas, A.
    de Curzon, Parent O.
    Sinegre, M.
    Paubel, P.
    VALUE IN HEALTH, 2015, 18 (07) : A678 - A678
  • [7] The Budget Impact of Orphan Drugs in the US: A 20072013 MIDAS Sales Data Analysis
    Divino, Victoria
    Dekoven, Mitch
    Wang, Weiying
    Kleinrock, Michael
    Harvey, R. Donald
    Wade, Rolin L.
    Kaura, Satyin
    BLOOD, 2014, 124 (21)
  • [8] THE BUDGET IMPACT OF ORPHAN DRUGS IN THE US AND CANADA: A 2007-2013 MIDAS SALES DATA ANALYSIS
    Divino, V
    DeKoven, M.
    Kim, T.
    Kleinrock, M.
    Wade, R. L.
    Kaura, S.
    VALUE IN HEALTH, 2015, 18 (07) : A666 - A666
  • [9] PRICING AND MARKET ACCESS OF ORPHAN DRUGS IN CHINA: ANALYSIS OF NATIONAL AND PROVINCIAL POLICY AND THE ASSOCIATED IMPACT ON COVERAGE
    Sherwin, G.
    Akpinar, P.
    Yap, B.
    VALUE IN HEALTH, 2016, 19 (07) : A835 - A835
1